aTyr Pharma, Inc. (NASDAQ:ATYR) — Market Cap & Net Worth
Market Cap & Net Worth: aTyr Pharma, Inc. (ATYR)
aTyr Pharma, Inc. (NASDAQ:ATYR) has a market capitalization of $47.65 Million ($47.65 Million) as of August 3, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #22009 globally and #4833 in its home market, demonstrating a -2.43% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying aTyr Pharma, Inc.'s stock price $0.49 by its total outstanding shares 98051212 (98.05 Million). See ATYR capex reinvestment rate to understand how much of operating cash flow is reinvested back into capital assets.
aTyr Pharma, Inc. Market Cap History: 2015 to 2026
aTyr Pharma, Inc.'s market capitalization history from 2015 to 2026. Data shows change from $13.49 Billion to $47.65 Million (-41.35% CAGR).
Index Memberships
aTyr Pharma, Inc. is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.46 Trillion | 0.00% | #628 of 976 |
Weight: aTyr Pharma, Inc.'s market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
aTyr Pharma, Inc. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how aTyr Pharma, Inc.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
404.13x
aTyr Pharma, Inc.'s market cap is 404.13 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2019 | $408.87 Million | $422.00K | -$23.60 Million | 968.89x | N/A |
| 2020 | $380.44 Million | $10.46 Million | -$16.22 Million | 36.39x | N/A |
| 2022 | $214.73 Million | $10.39 Million | -$45.34 Million | 20.68x | N/A |
| 2023 | $138.25 Million | $353.00K | -$50.39 Million | 391.65x | N/A |
| 2024 | $354.95 Million | $235.00K | -$64.02 Million | 1510.41x | N/A |
| 2025 | $76.78 Million | $190.00K | -$74.12 Million | 404.13x | N/A |
Competitor Companies of ATYR by Market Capitalization
Companies near aTyr Pharma, Inc. in the global market cap rankings as of August 3, 2026.
Key companies related to aTyr Pharma, Inc. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #220 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #424 globally with a market cap of $64.60 Billion USD.
- Argen-X (BR:ARGX): Ranked #543 globally with a market cap of $49.55 Billion USD ( €42.38 Billion EUR).
- UCB SA (BR:UCB): Ranked #563 globally with a market cap of $47.34 Billion USD ( €40.49 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #220 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $477.10 |
| #424 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $64.60 Billion | $762.63 |
| #543 | Argen-X | BR:ARGX | $49.55 Billion | €745.00 |
| #563 | UCB SA | BR:UCB | $47.34 Billion | €222.90 |
aTyr Pharma, Inc. Historical Marketcap From 2015 to 2026
Between 2015 and today, aTyr Pharma, Inc.'s market cap moved from $13.49 Billion to $ 47.65 Million, with a yearly change of -41.35%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $47.65 Million | -37.94% |
| 2025 | $76.78 Million | -78.37% |
| 2024 | $354.95 Million | +156.74% |
| 2023 | $138.25 Million | -35.62% |
| 2022 | $214.73 Million | -70.68% |
| 2021 | $732.44 Million | +92.53% |
| 2020 | $380.44 Million | -6.95% |
| 2019 | $408.87 Million | -39.95% |
| 2018 | $680.87 Million | -85.83% |
| 2017 | $4.80 Billion | +62.79% |
| 2016 | $2.95 Billion | -78.13% |
| 2015 | $13.49 Billion | -- |
End of Day Market Cap According to Different Sources
On Aug 3rd, 2026 the market cap of aTyr Pharma, Inc. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $47.65 Million USD |
| MoneyControl | $47.65 Million USD |
| MarketWatch | $47.65 Million USD |
| marketcap.company | $47.65 Million USD |
| Reuters | $47.65 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About aTyr Pharma, Inc.
aTyr Pharma, Inc., a clinical stage biotechnology company, engages in the discovery and development of product candidates that translate tRNA synthetase biology into new therapies for fibrosis and inflammation in the United States. Its lead therapeutic candidate efzofitimod, a selective modulator of NRP2 that is in Phase 3 clinical trial for the treatment of pulmonary sarcoidosis; Phase 2 clinica… Read more